PRNewsWire
16 Jun 2026, 03:14 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
PTC Therapeutics priced a $500 million offering of 0% Convertible Senior Notes due 2031. — The company is securing low-cost, non-interest-bearing capital, which improves the balance sheet but introduces potential future dilution.
+0.20The conversion price is set at $107.48, representing a 40% premium over the closing price of $76.77. — A high conversion premium suggests management's confidence in stock appreciation and delays immediate dilution.
+0.10Approximately $328.8 million of the proceeds will be used to repurchase $222 million of 1.5% Convertible Senior Notes due 2026. — This is a standard refinancing move that extends the company's debt maturity profile and reduces immediate interest expense.
+0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is refinancing debt with a new 0% interest offering, which reduces interest expenses and extends maturity.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
8h ago
